Search tips
ECCMID 2023
Courses & Events
Guidelines
From the archive: ECCMID and more before 2010
Search Results
Sort by:
Filter 0
Sort by
Filter
Sort by
Relevance
Date descending
Date ascending
22 April 2022 - P0763
Comparison of lefamulin MIC Test Strip (MTS) to broth microdilution MIC for Streptococcus spp., S. aureus, M. catarrhalis, and Haemophilus spp.
Laura Koeth, Jeanna Difranco-Fisher, Dwight Hardy, Elizabeth Palavecino, Edoardo Carretto, Susanne Paukner
22 April 2022 - P0487
Lefamulin activity against bacterial pathogens typically causing pneumonia collected from European Medical Centres in 2020 and 2021
Helio S. Sader, S.j. Ryan Arends, Rodrigo E. Mendes, Steven P. Gelone, Susanne Paukner
22 April 2022 - P0486
Lefamulin activity against a contemporary global collection of Staphylococcus aureus (SENTRY 2020-2021)
Susanne Paukner, S. J. Ryan Arends, Steven P. Gelone, Rodrigo E. Mendes, Helio S. Sader
22 April 2022 - P1393
Evaluation of the Oxoid Lefamulin 20 µg Antimicrobial Susceptibility Testing (AST) Disc against the hardy Lefamulin 20 µg AST Disc
Amie Lovatt, Nicole Holliday, Cindy Knapp, Edward Best, Susanne Paukner, Katie Simpson, Jill Lindley, Dee Shortridge
22 April 2022 - L0110
Phenotypic and genotypic antimicrobial susceptibility patterns of the emerging human respiratory pathogen Mycoplasma amphoriforme isolated from the United Kingdom and Denmark
Jessica Day, Baharak Afshar, Richard Rowlands, Taiba Umer, Helena Windsor, Susanne Paukner, Jorgen Jensen, Brad Spiller, Victoria Chalker, Michael Beeton
08 July 2021 - 1381
In vitro activity of lefamulin against Staphylococcus aureus and Haemophilus influenzae, common pathogens in cystic fibrosis (CF), collected from non-CF paediatric patients (SENTRY Surveillance 2015-2019)
Susanne Paukner, S. Paukner (1), R.S.J. Arends (2), J. Schranz (3), S.P. Gelone (3), H.S. Sader (2)
15 April 2019 - O1068
Oral lefamulin demonstrates favorable safety and tolerability in adults with community-acquired bacterial pneumonia in the phase III lefamulin evaluation against pneumonia (LEAP 2) study
Jennifer Schranz, Elizabeth Alexander, Lisa Goldberg, Anita Das, Gregory Moran, Christian Sandrock, Leanne Gasink, Patricia Spera, Carolyn Sweeney, Susanne Paukner, Wolfgang W. Wicha
14 April 2019 - P1828
In vitro activity of lefamulin against isolates commonly causing community-acquired bacterial pneumonia collected during the SENTRY surveillance programme 2017 in Europe
Susanne Paukner, Steve P. Gelone, Helio S. Sader
14 April 2019 - P1823
Antimicrobial activity of lefamulin against a large longitudinal collection of clinical bacterial isolates collected worldwide: results from the SENTRY antimicrobial surveillance program
Helio S. Sader, Susanne Paukner, SJ Ryan Arends, Steven P Gelone, Rodrigo E. Mendes
14 April 2019 - P1946
Pharmacokinetic-pharmacodynamic (PK-PD) target attainment analyses to support lefamulin dose justification and susceptibility breakpoint determinations for patients with community-acquired bacterial pneumonia (CABP)
Nikolas J. Onufrak, Sujata M. Bhavnani, Jeffrey P. Hammel, Wolfgang W. Wicha, Susanne Paukner, Helio S. Sader, Christopher M. Rubino, Jennifer Schranz, Steve P. Gelone, Paul G. Ambrose
22 April 2018 - P1823
In vitro activity of lefamulin against contemporary Staphylococcus aureus isolates from patients in Europe (SENTRY 2016)
Susanne Paukner, S. Paukner, R. Flamm, R. Mendes, S. Gelone, H. Sader
23 April 2017 - P1335
Lefamulin is highly active in-vitro against multi-drug-resistant mycoplasma genitalium strains
Susanne Paukner, Jorgen Skov Jensen
23 April 2017 - P1331
In vitro activity of lefamulin against bacterial pathogens commonly causing community-acquired bacterial pneumonia (CAP): 2015 SENTRY data from Europe
Susanne Paukner, Helio S. Sader, Jennifer Streit, Robert Flamm, Steve Gelone
23 April 2017 - P1334
In vitro activity of lefamulin against a global collection of respiratory pathogens from paediatric patients from the 2015 SENTRY programme
Susanne Paukner, Robert Flamm, Leonard Duncan, Steve Gelone, Helio S. Sader
23 April 2017 - P1333
In Vitro Activity of Lefamulin against S. aureus Collected from Hospitalized Patients with Bacterial Pneumonia in Europe
Susanne Paukner, Robert Flamm, Jennifer Streit, Steve Gelone, Helio S. Sader
23 April 2017 - P1332
In Vitro Activity of Lefamulin against Staphylococccus aureus from Hospital-Acquired Pneumonia (HAP) and Community-Acquired Pneumonia (CAP) Patients in Europe
Susanne Paukner, Helio S. Sader, Robert Flamm, Leonard Duncan, Steve Gelone
22 April 2017 - EP0405
Lefamulin selectively inhibits bacterial protein synthesis
Susanne Paukner, Astrid Gruss, Rosemarie Riedl
10 April 2016 - P1333
Activity of Debio 1452 against Staphylococcus spp. collected in 2013/2014
Susanne Paukner, Paukner Susanne, Dieppois Guennaëlle, S. Hawser, M. Gueny, C. Le Bras, I. Morrissey, T. Valmont, S. Magnet, F. Wittke, G. Dieppois
24 April 2015 - P0248
Kill curves of the novel extended-spectrum pleuromutilin antibiotic BC-9529
Susanne Paukner, Paukner, Susanne *; Kollmann, Hermann; Riedl, Rosemarie; Ivezic-Schoenfeld, Zrinka;
24 April 2015 - P0247
In vitro and in vivo efficacy of novel extended-spectrum pleuromutilins against S. aureus and S. pneumoniae
Susanne Paukner, Paukner, Susanne *; Wicha, Wolfgang; Thirring, Klaus; Kollmann, Hermann; Ivezic-Schoenfeld, Zrinka;
Loading ...
+ load more
FAQ
To access content in the eLibrary you need to log in with your ESCMID member or user credentials. If you haven’t registered as an ESCMID member yet, then click here to do so – or use this link to register as a user.
The most recent event-related content is usually restricted to ESCMID members, while registered users get access one year after the event. However, there are events such as ECCMID where attendees get priority access, no matter if they are members or registered users. In these cases, we may offer non-attendees access after paying a fee.
You may search by event name, session title or number, topic title or number or author – or by any keyword. To get the most relevant results, enter the title or name in quotation marks, e.g. "Pre-ECCMID Day on Diagnostics" or "John Doe". If no quotation marks are used, then the exact result is shown first, followed by less exact results.
You may further narrow the number of search results for most terms by applying one or several filters, using the filter window on the start page. The Category and Media Type filters work for any content. In contrast, the Date from / to filter may not apply for Publications and Guidelines. In addition, the information text below a webcast or document offers the option of filtering search results by session title, author, event or category.
We defined four "hot topic" terms that you may search for by clicking the four tiles on the start page.
Linking two or more search terms by AND will show all results containing these search terms. For example, if you are looking for results that contain both the terms viral and hospital, then enter viral AND hospital.
Link two or more search terms by OR to get all results that contain at least one of these terms. For example, if you want to get results that contain either viral or infections or COVID, then enter viral OR infections OR COVID.
Place + in front of the term that you want to be included in your search result and place - in front of the term that you do not want to be included – without blanks in between in either case. For example, if you are aiming for search results that contain viral and infection but do not contain COVID, then enter +viral +infections -COVID.
A search term preceded by an exclamation point (no blanks in between) will lead to all content that does not contain the term, e.g. !COVID.
Deselect the ticked boxes in the filter dropdowns, click "Clear" on the calendars in the Date from / to filter – or refresh the website to remove all filters at once. Additionally, you may clear all applied filters by using the relevant buttons right above the search results.
No, as copyright protection limits the viewing of video presentations to web browsers, they cannot be downloaded.
No, due to our privacy policy we cannot disclose any contact details of persons involved.